Sanofi patents expiration
1. Hectorol patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6903083 | SANOFI | Stabilized hydroxyvitamin D |
Jul, 2021
(2 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5602116 | SANOFI | Method for treating and preventing secondary hyperparathyroidism |
Feb, 2014
(10 years ago) | |
| US7148211 | SANOFI | Formulation for lipophilic agents |
Sep, 2023
(7 months ago) | |
Drugs and Companies using DOXERCALCIFEROL ingredient
Market Authorisation Date: 23 April, 2004
Treatment: Reduction of elevated ipth levels in the mgt of secondary hyperparathyroidism in patients undergong chronic renal dialysis
Dosage: CAPSULE;ORAL; INJECTABLE;INJECTION
How can I launch a generic of HECTOROL before it's drug patent expiration?
More Information on Dosage
HECTOROL family patents
2. Renvela patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6858203 | SANOFI | Method of making phosphate-binding polymers for oral administration |
Aug, 2013
(10 years ago) | |
| US7459151 | SANOFI | Phosphate-binding polymers for oral administration |
Aug, 2013
(10 years ago) | |
| US5496545 | SANOFI | Phosphate-binding polymers for oral administration |
Aug, 2013
(10 years ago) | |
| US6509013 | SANOFI | Method of making phosphate-binding polymers for oral administration |
Aug, 2013
(10 years ago) | |
| US7014846 | SANOFI | Phosphate-binding polymers for oral administration |
Aug, 2013
(10 years ago) | |
| US5667775 | SANOFI | Phosphate-binding polymers for oral administration |
Sep, 2014
(9 years ago) | |
| US7985418 | SANOFI | Aliphatic amine polymer salts for tableting |
Oct, 2025
(1 year, 6 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Nov 25, 2019 |
Drugs and Companies using SEVELAMER CARBONATE ingredient
Market Authorisation Date: 19 October, 2007
Treatment: Phosphate binding
Dosage: TABLET;ORAL
How can I launch a generic of RENVELA before it's drug patent expiration?
More Information on Dosage
RENVELA family patents